CL2020001093A1 - Proceso para preparar el benzotiofen-2-il boronato. - Google Patents

Proceso para preparar el benzotiofen-2-il boronato.

Info

Publication number
CL2020001093A1
CL2020001093A1 CL2020001093A CL2020001093A CL2020001093A1 CL 2020001093 A1 CL2020001093 A1 CL 2020001093A1 CL 2020001093 A CL2020001093 A CL 2020001093A CL 2020001093 A CL2020001093 A CL 2020001093A CL 2020001093 A1 CL2020001093 A1 CL 2020001093A1
Authority
CL
Chile
Prior art keywords
benzothiophen
boronate
prepare
drugs
production
Prior art date
Application number
CL2020001093A
Other languages
English (en)
Inventor
Johannes Platzek
Jörg Gries
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60293714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020001093(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2020001093A1 publication Critical patent/CL2020001093A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

UN PROCESO PARA PREPARAR EL BENZOTIOFEN-2-IL BORONATO DE LA FÓRMULA (VI), QUE SIRVE COMO INTERMEDIARIO PARA LA PRODUCCIÓN DE MEDICAMENTOS Y PARA LA PRODUCCIÓN DE MEDICAMENTOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DE TRASTORNOS PROLIFERATIVOS, COMO, POR EJEMPLO, CÁNCER Y ENFERMEDADES TUMORALES.
CL2020001093A 2017-10-25 2020-04-23 Proceso para preparar el benzotiofen-2-il boronato. CL2020001093A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17198336 2017-10-25

Publications (1)

Publication Number Publication Date
CL2020001093A1 true CL2020001093A1 (es) 2020-10-23

Family

ID=60293714

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001093A CL2020001093A1 (es) 2017-10-25 2020-04-23 Proceso para preparar el benzotiofen-2-il boronato.

Country Status (20)

Country Link
US (2) US11274110B2 (es)
EP (1) EP3700894A1 (es)
JP (1) JP2021500392A (es)
KR (1) KR20200074128A (es)
CN (1) CN111225907B (es)
AR (1) AR113793A1 (es)
AU (1) AU2018354780A1 (es)
BR (1) BR112020008063A2 (es)
CA (1) CA3084755A1 (es)
CL (1) CL2020001093A1 (es)
CO (1) CO2020004984A2 (es)
IL (1) IL273952A (es)
JO (1) JOP20200090A1 (es)
MX (1) MX2020004285A (es)
PE (1) PE20211268A1 (es)
SG (1) SG11202002199RA (es)
TW (1) TWI784074B (es)
UA (1) UA126592C2 (es)
UY (1) UY37949A (es)
WO (1) WO2019081346A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
IL301396A (en) 2020-09-30 2023-05-01 Nobell Foods Inc Recombinant milk proteins and food compositions comprising the same
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030355A1 (it) * 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
EP2134683A2 (en) * 2007-02-12 2009-12-23 Intermune, Inc. Novel inhibitors hepatitis c virus replication
EP2338887A4 (en) 2008-10-15 2012-05-09 Kissei Pharmaceutical FUSIONED HETEROCYCLIC DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
JP6047582B2 (ja) * 2011-12-15 2016-12-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換ベンゾチエニル−ピロロトリアジンおよび癌の処置におけるその使用

Also Published As

Publication number Publication date
TWI784074B (zh) 2022-11-21
CO2020004984A2 (es) 2020-05-05
IL273952A (en) 2020-05-31
US11274110B2 (en) 2022-03-15
AR113793A1 (es) 2020-06-10
TW201925211A (zh) 2019-07-01
PE20211268A1 (es) 2021-07-19
SG11202002199RA (en) 2020-04-29
RU2020115600A (ru) 2021-11-25
MX2020004285A (es) 2020-07-29
RU2020115600A3 (es) 2022-03-29
BR112020008063A2 (pt) 2020-11-03
JP2021500392A (ja) 2021-01-07
AU2018354780A1 (en) 2020-04-09
UY37949A (es) 2019-05-31
US20200339606A1 (en) 2020-10-29
CN111225907A (zh) 2020-06-02
KR20200074128A (ko) 2020-06-24
US20220356194A1 (en) 2022-11-10
EP3700894A1 (en) 2020-09-02
WO2019081346A1 (en) 2019-05-02
CN111225907B (zh) 2023-05-26
JOP20200090A1 (ar) 2020-05-03
UA126592C2 (uk) 2022-11-02
CA3084755A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
CO2020013155A2 (es) Moduladores de nlrp3
AR134579A2 (es) Proceso para la preparación de un compuesto de diariltiohidantoína
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
JOP20200152A1 (ar) مركبات حلقية كبرى لعلاج مرض
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CO2020000227A2 (es) Moduladores de nlrp3
MX380907B (es) Compuestos útiles como inhibidores de cinasa.
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EP4552697A3 (en) Protein kinase c inhibitors and methods of their use
MX394645B (es) Compuestos heteroaromáticos como inhibidores de vanina.
MX2019012734A (es) Procesos para la preparacion de un compuesto de diariltiohidantoina.
MX391474B (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MY195000A (en) Method for the treatment of neurological disease
MX369857B (es) Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
CO2020004984A2 (es) Proceso para preparar el benzotiofen-2-il boronato
MX380776B (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
MX2019003311A (es) Metodos para tratamiento de cancer de ovario.
PH12017501063A1 (en) Compounds for the treatment of cancer